VBI Vaccines EBIT

VBI Vaccines (VBIV) currently reports a EBIT of $-52M as of March 2024. That compares with $-85M in the prior-year period — up 39.3% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore VBI Vaccines's EBIT history and peer comparisons.

VBI Vaccines's EBIT increased from $-85M to $-52M — a 39.3% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

VBI Vaccines's EBIT of $-52M is lower than the Healthcare sector average of $99B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

VBI Vaccines reported $-52M in EBIT as of March 2024. That compares with $-85M in the prior-year period — up 39.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-52M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for VBI Vaccines, and consider following VBIV for alerts when major investors trade the stock.